EP2753641A4 - Neuroprotective cell-penetrating peptides - Google Patents
Neuroprotective cell-penetrating peptidesInfo
- Publication number
- EP2753641A4 EP2753641A4 EP12830062.1A EP12830062A EP2753641A4 EP 2753641 A4 EP2753641 A4 EP 2753641A4 EP 12830062 A EP12830062 A EP 12830062A EP 2753641 A4 EP2753641 A4 EP 2753641A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- penetrating peptides
- neuroprotective cell
- neuroprotective
- cell
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20115870A FI20115870A0 (en) | 2011-09-05 | 2011-09-05 | Neuroprotective cell penetrating peptides |
PCT/FI2012/050859 WO2013034805A1 (en) | 2011-09-05 | 2012-09-05 | Neuroprotective cell-penetrating peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2753641A1 EP2753641A1 (en) | 2014-07-16 |
EP2753641A4 true EP2753641A4 (en) | 2015-06-24 |
Family
ID=44718780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12830062.1A Withdrawn EP2753641A4 (en) | 2011-09-05 | 2012-09-05 | Neuroprotective cell-penetrating peptides |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2753641A4 (en) |
FI (1) | FI20115870A0 (en) |
WO (1) | WO2013034805A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2820424B1 (en) | 2012-01-24 | 2016-12-07 | University of Massachusetts | Soluble manf in pancreatic beta-cell disorders |
WO2014191630A2 (en) * | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
US10265380B2 (en) | 2014-03-05 | 2019-04-23 | Amarantus Bioscience Holdings, Inc. | Method of administering MANF for the protection of sensory cells |
EP3122370A1 (en) * | 2014-03-28 | 2017-02-01 | Buck Institute for Research on Aging | Methods and compositions for modulating the immune system |
US20170157243A1 (en) * | 2014-06-24 | 2017-06-08 | University Of Massachusetts | MANF as a Regulator of Immune System Function |
EP3377089B1 (en) | 2015-11-18 | 2020-04-08 | Herantis Pharma Plc | Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases |
JP7384672B2 (en) * | 2017-05-04 | 2023-11-21 | ヘルシンギン ユリオピスト | C-terminal CDNF fragments and C-terminal MANF fragments, pharmaceutical compositions containing them, and uses thereof |
EP3774858A1 (en) * | 2018-03-29 | 2021-02-17 | Helsingin Yliopisto | C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof |
EP3838912A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptides |
EP3838345A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Macrocyclic peptides |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043693A1 (en) * | 1998-02-26 | 1999-09-02 | Human Genome Sciences, Inc. | 36 human secreted proteins |
WO2002074956A2 (en) * | 2001-03-20 | 2002-09-26 | Prescient Neuropharma Inc. | Dopaminergic neuronal survival-promoting factors and uses thereof |
WO2002079246A2 (en) * | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
US20030109690A1 (en) * | 1999-09-29 | 2003-06-12 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
US20030109457A1 (en) * | 2001-10-25 | 2003-06-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
WO2004050688A1 (en) * | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
WO2009133247A1 (en) * | 2008-04-30 | 2009-11-05 | Licentia Oy | Neurotrophic factor manf and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1969003B8 (en) * | 2005-12-14 | 2010-11-10 | Hermo Pharma Ltd. | Uses of a NEUROTROPHIC FACTOR PROTEIN |
-
2011
- 2011-09-05 FI FI20115870A patent/FI20115870A0/en not_active Application Discontinuation
-
2012
- 2012-09-05 EP EP12830062.1A patent/EP2753641A4/en not_active Withdrawn
- 2012-09-05 WO PCT/FI2012/050859 patent/WO2013034805A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043693A1 (en) * | 1998-02-26 | 1999-09-02 | Human Genome Sciences, Inc. | 36 human secreted proteins |
US20030109690A1 (en) * | 1999-09-29 | 2003-06-12 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
WO2002074956A2 (en) * | 2001-03-20 | 2002-09-26 | Prescient Neuropharma Inc. | Dopaminergic neuronal survival-promoting factors and uses thereof |
WO2002079246A2 (en) * | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
US20030109457A1 (en) * | 2001-10-25 | 2003-06-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
WO2004050688A1 (en) * | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
WO2009133247A1 (en) * | 2008-04-30 | 2009-11-05 | Licentia Oy | Neurotrophic factor manf and uses thereof |
Non-Patent Citations (6)
Title |
---|
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 June 2003 (2003-06-12), Database accession no. 536071-66-6 * |
JORDAN M. FLETCHER ET AL: "Novel monocyclic and bicyclic loop mimetics of brain-derived neurotrophic factor", JOURNAL OF PEPTIDE SCIENCE, vol. 12, no. 8, 1 January 2006 (2006-01-01), pages 515 - 524, XP055145298, ISSN: 1075-2617, DOI: 10.1002/psc.760 * |
M. HELLMAN: "Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) Has a Unique Mechanism to Rescue Apoptotic Neurons", J. BIOL. CHEM., vol. 286, no. 4, 1 January 2011 (2011-01-01), pages 2675 - 2680, XP055145300 * |
PÄIVI LINDHOLM ET AL: "Novel CDNF/MANF family of neurotrophic factors", DEVELOPMENTAL NEUROBIOLOGY, 1 January 2010 (2010-01-01), pages NA - NA, XP055145301, ISSN: 1932-8451, DOI: 10.1002/dneu.20760 * |
See also references of WO2013034805A1 * |
VICTOR J. HRUBY: "Designing peptide receptor agonists and antagonists", NATURE REVIEWS DRUG DISCOVERY, vol. 1, no. 11, 1 November 2002 (2002-11-01), pages 847 - 858, XP055034286, ISSN: 1474-1776, DOI: 10.1038/nrd939 * |
Also Published As
Publication number | Publication date |
---|---|
EP2753641A1 (en) | 2014-07-16 |
WO2013034805A1 (en) | 2013-03-14 |
FI20115870A0 (en) | 2011-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243427A1 (en) | Therapeutic peptides | |
IL233280A0 (en) | Cell-penetrating peptides | |
SG11201401043SA (en) | P53 activating peptides | |
EP2857033A4 (en) | Skin-permeating peptide | |
EP2753641A4 (en) | Neuroprotective cell-penetrating peptides | |
GB201012651D0 (en) | Peptides | |
ZA201307169B (en) | Neuroprotective peptides | |
EP2812347A4 (en) | Autophagy-inducing peptide | |
GB201111183D0 (en) | Peptide | |
GB201115910D0 (en) | Peptides | |
HK1209138A1 (en) | Peptides | |
EP2627674A4 (en) | Egfr-based peptides | |
EP2793918A4 (en) | Hdc-sign binding peptides | |
GB201204868D0 (en) | Peptides | |
GB201200555D0 (en) | Peptide | |
HK1187628A1 (en) | Novel peptide | |
EP2714717A4 (en) | Phoenixin peptides | |
PT2891663T (en) | Psf1-derived peptides | |
IL228354A0 (en) | Neuroprotective peptides | |
GB201115014D0 (en) | Peptides | |
GB201220328D0 (en) | Peptides | |
GB201211740D0 (en) | Peptides | |
AU2011903086A0 (en) | Peptides | |
GB201207895D0 (en) | Peptides | |
GB201200509D0 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140317 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150526 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20150519BHEP Ipc: A61K 38/18 20060101ALI20150519BHEP Ipc: C07K 14/475 20060101AFI20150519BHEP Ipc: A61P 5/00 20060101ALI20150519BHEP Ipc: A61P 25/00 20060101ALI20150519BHEP Ipc: A61P 25/30 20060101ALI20150519BHEP Ipc: C07K 5/103 20060101ALI20150519BHEP Ipc: A61P 25/16 20060101ALI20150519BHEP Ipc: A61K 38/07 20060101ALI20150519BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151223 |